Tag Archive for: Conference

Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis

/in

Edinburgh and London, UK, 10 December 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company focused on pioneering regenerative macrophage therapy (“RMT”) in inflammatory and fibrotic diseases,  today announces it has presented a poster at the Keystone Symposia Fibrosis: Inflammation, Drivers, and Therapeutic Resolution taking place on 8 – 11 December 2024 in […]

Read more

Weekly round-up: Optimum’s clients show their expertise, as excitement builds ahead of Scrip Awards

/in

It’s been a busy week for Optimum, with some amazing original content from our clients, with this week’s podcast highlighting their expertise in cutting-edge lung cancer research. In our weekly hot topic article, they give predictions for the 2025 outlook following November’s London Life Sciences Week. We also have five clients nominated for the prestigious […]

Read more

Mapping out the top life science conferences to attend in the next 6 months

/in

Will we see you there? The Optimum team has taken a moment to map out the top life science conferences to attend in the next six months. Believe it or not, now is the time to be organising your 2025 conference calendar to maximise the opportunities these major life sciences events present. Secure your travel […]

Read more

Optimum Strategic Communications to Host 16th Annual Healthcare Investor Conference with ‘Back to Growth’ theme

/in ,

LONDON, Oct. 8, 2024 /PRNewswire/ — Optimum Strategic Communications (Optimum), the international strategic healthcare communications consultancy, will be hosting its 16th Annual Healthcare Investor Conference on Thursday 10 October, 2024 at The Kings Fund, London. This year, as markets begin to bounce back after a lacklustre period, a prestigious line-up of industry experts will look to growth, identifying which therapies will attract investor […]

Read more

Weekly wrap-up: $100m Series B financing for a bivalent vaccine, to new clinical data from a cutting-edge antibody-drug conjugate…

/in

Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine  Vicebio Ltd, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, on Monday announced a $100 million Series B financing  led by TCGX  with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio,  and participation from UniQuest and founding investor Medicxi.  London-based Vicebio said funding […]

Read more